Vext Science (VEXT) AI Stock Analysis

• Market Cap: $71.80M
• Dividend Yield: N/A
• Average Volume (3M): 43.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.20
• Revenue Growth: 36.50%
• EPS Growth: -306.47%
• Country: CA
• Employees: 173
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 180,306,050
• 10 Day Avg. Volume: 41,604
• 30 Day Avg. Volume: 43,444
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.15
• Enterprise Value/Revenue: 1.87
• Enterprise Value/Gross Profit: 6.24
• Enterprise Value/Ebitda: 13.19
• 1Y Price Target: $0.50
• Price Target Upside: 66.27% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: C$0.50 ▲(66.67% Upside)

Vext Science's overall stock score reflects a blend of strong technical indicators and positive earnings call insights, particularly in Ohio, which are offset by concerns over profitability and valuation. The company's ability to capitalize on growth opportunities while addressing profitability challenges will be crucial for future performance.

Vext Science Business Overview & Revenue Model

Company Description

Vext Science, Inc., through its subsidiaries, operates as an integrated agricultural technology, services, and property management company in the cannabis industry in the United States. The company is involved in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, and edibles. It also engages in the retail dispensary activities; and wholesale distribution of cannabis THC and hemp CBD products under the Vapen and Pure Touch Botanicals brands. In addition, the company offers Vapen clear infused products, THC chocolate bars, THC syrup, THC snacks, candies, and gummies under Vapen Kitchens brand. The company was formerly known as Vapen MJ Ventures Corporation and changed its name to Vext Science, Inc. in November 2019. Vext Science, Inc. was incorporated in 2015 and is headquartered in Phoenix, Arizona .

How the Company Makes Money

Vext Science generates revenue through multiple streams, primarily from the sale of its cannabis products, including dried flower, oils, and edibles. The company has established a strong presence in key markets, allowing it to capitalize on the increasing demand for cannabis products. Additionally, VEXT engages in wholesale distribution, supplying its products to dispensaries, which contributes significantly to its revenue. The company may also benefit from strategic partnerships with other cannabis operators and retailers, enhancing its market reach and operational efficiency. Furthermore, Vext Science's commitment to quality and compliance helps to build brand loyalty and repeat business, which are essential for sustaining its revenue growth.

Vext Science Financial Statement Overview

Summary

Vext Science shows revenue growth but faces profitability challenges with negative net profit and EBIT margins. The balance sheet is moderately leveraged, and while cash flow has improved, historical volatility poses sustainability risks.

Income Statement

Vext Science shows fluctuating financial performance with recent revenue growth of 8.8% in the TTM period. The gross profit margin decreased from the previous year, and the company is currently experiencing negative net profit and EBIT margins, indicating profitability challenges. Despite some revenue growth, the declining profitability metrics present significant concerns.

Balance Sheet

The balance sheet reveals moderate financial leverage with a debt-to-equity ratio of 0.52 in the TTM period, indicating manageable debt levels. However, the equity ratio has declined over time, reflecting increased liabilities. Return on equity is negative due to net losses, highlighting challenges in generating returns for shareholders.

Cash Flow

Vext Science has shown improvement in operating cash flow, with a positive free cash flow in the TTM period. The operating cash flow to net income ratio indicates strong cash generation relative to reported losses, suggesting efficient cash management. However, the historical volatility in free cash flow growth poses a risk to sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	44.15M	36.00M	34.81M	35.41M	37.24M	25.19M
Gross Profit	13.25M	8.98M	12.04M	23.10M	18.69M	11.20M
EBITDA	6.27M	-2.02M	16.77M	15.03M	12.80M	5.52M
Net Income	-16.52M	-22.44M	4.40M	10.92M	4.99M	2.13M
Balance Sheet
Total Assets	132.88M	136.97M	149.56M	120.52M	83.70M	55.45M
Cash, Cash Equivalents and Short-Term Investments	4.55M	4.62M	8.72M	5.93M	6.47M	1.75M
Total Debt	35.62M	39.52M	38.60M	38.15M	14.10M	11.49M
Total Liabilities	61.84M	61.23M	54.58M	48.60M	24.31M	19.14M
Stockholders Equity	71.04M	75.74M	94.98M	71.92M	59.39M	36.31M
Cash Flow
Free Cash Flow	8.65M	1.82M	1.69M	-2.94M	-7.10M	-964.90K
Operating Cash Flow	11.03M	3.29M	4.42M	5.92M	11.68M	3.10M
Investing Cash Flow	-4.99M	-5.44M	-4.82M	-30.31M	-27.10M	-12.90M
Financing Cash Flow	-4.88M	-1.95M	3.19M	23.86M	20.14M	4.26M

Vext Science Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VEXT, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.24, and above the 200-day MA of 0.17, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 56.59 is Neutral, neither overbought nor oversold. The STOCH value of 26.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:VEXT.

Vext Science Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DB	76 Outperform	72.09M	4.81	13.88%	―	-0.53%	0.00%
VEXT	61 Neutral	$71.80M	―	-20.91%	―	36.50%	-306.47%
ROMJ	60 Neutral	39.63M	218.52	0.55%	―	34.19%	0.00%
CXXI	56 Neutral	54.76M	-11.92	-13.84%	―	21.71%	18.75%
LABS	45 Neutral	29.45M	-3.35	-21.74%	―	17.74%	37.61%
GWAY	44 Neutral	23.80M	-14.06	0.00%	―	26.75%	61.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Vext Science Corporate Events

Vext Science to Release Q2 2025 Financial Results on August 20

Vext Science, Inc. announced it will release its financial results for the second quarter of 2025 on August 20, 2025. The company will host a conference call and webcast to discuss these results, which could provide insights into its operational performance and strategic positioning in the cannabis industry. This announcement is significant for stakeholders as it may impact perceptions of Vext’s financial health and future growth prospects in its core markets.

Vext Science Expands Ohio Footprint with New Fairfield Dispensary

Vext Science, Inc. has secured a provisional license for its sixth cannabis dispensary in Fairfield, Ohio, with operations expected to commence in the fourth quarter of 2025, subject to regulatory approvals. This strategic expansion highlights Vext’s disciplined approach to growth, leveraging high-traffic locations and limited competition to drive cash flow and shareholder value. The new Fairfield location, adjacent to Jungle Jim’s International Market, is expected to enhance visibility and consumer traffic, further solidifying Vext’s market position in Ohio as it approaches the state’s dispensary license cap of eight.

Vext Science Expands Ohio Presence with Fifth Dispensary Opening

Vext Science, Inc. has opened its fifth cannabis dispensary in Portsmouth, Ohio, enhancing its retail footprint in the state. The new location, which includes a drive-thru, is part of Vext’s strategy to scale its operations and increase market presence in Ohio, a key growth area for the company. The Portsmouth dispensary is expected to be fully consolidated by late 2025, subject to regulatory approval. Vext’s vertically integrated model in Ohio positions it to drive margin expansion and free cash flow, supporting its long-term growth and shareholder value.

Vext Science, Inc. Transitions to New Auditor Amid Growth

Vext Science, Inc. has announced a change of auditor from Reliant CPA to MNP LLP, effective June 4, 2025. The change was initiated by the former auditor due to the company’s growth exceeding its audit practice’s scope. The new auditor, MNP LLP, is expected to better meet Vext’s financial reporting needs due to its greater public company experience. The transition is not associated with any reservations or reportable events, and has been approved by the board.

Vext Science Achieves Record Q1 Revenue and Expands Ohio Footprint

Vext Science reported a record Q1 performance with $11.6 million in revenue, a 38% increase from Q1 2024, driven by growth in Ohio. The company’s operating cash flow reached $3.1 million, matching its entire 2024 cash generation, highlighting the success of its retail strategy. Vext doubled its Ohio retail footprint by acquiring two dispensaries, enhancing its market presence. The company is focused on expanding in Ohio, reducing debt, and delivering sustainable returns for shareholders.